#2683099
Níl aon úsáid theiripeach ag ADB-BUTINACA agus níl údarú margaíochta táirge íocshláinte faighte ina leith.
ADB-BUTINACA has no therapeutic uses and it has not received a medicinal product marketing authorisation.
Scag na torthaí
Bailiúcháin
10 dtoradh in 2 dhoiciméad
#2683102
Braitheadh ADB-BUTINACA i 26 Bhallstát agus rialaítear é i gcúig Bhallstát ar a laghad.
ADB-BUTINACA has been detected in 26 Member States and is controlled in at least five Member States.
#2683103
Tá dian-fhaireachán á dhéanamh ar ADB-BUTINACA faoi láthair ag EMCDDA.
ADB-BUTINACA is subject to intensive monitoring by the EMCDDA.
#2683105
Luaitear ADB-BUTINACA in dhá fholáireamh a bhaineann leis an tsláinte phoiblí freisin.
ADB-BUTINACA is also mentioned in two additional public health-related alerts.
#2683101
Dá bhrí sin, molann EDS go gcuirtear ADB-BUTINACA i Sceideal II a ghabhann leis an gCoinbhinsiún maidir le Substaintí Síceatrópacha.
Thus, the WHO recommends that ADB-BUTINACA is placed in Schedule II of the Convention on Psychotropic Substances.
#2683107
Dá bhrí sin, ba cheart é a bheith mar sheasamh ag an Aontas ADB-BUTINACA a chur le Sceideal II a ghabhann leis an gCoinbhinsiún maidir le Substaintí Síceatrópacha.
Therefore, the position of the Union should be to add ADB-BUTINACA to Schedule II of the Convention on Psychotropic Substances.
#2683177
Tá ADB-BUTINACA le cur le Sceideal II a ghabhann leis an gCoinbhinsiún maidir le Substaintí Síceatrópacha.
ADB-BUTINACA is to be included in Schedule II of the Convention on Psychotropic Substances.
#2270281
Ag féachaint do Chinneadh ADB (D) 03-2021 lena leagtar síos rialacha inmheánacha maidir le srianta ar chearta áirithe de dhaoine is ábhar do na sonraí i ndáil le sonraí pearsanta a phróiseáil faoi chuimsiú fheidhmiú Chomhghnóthas SESAR,
Having regard to ADB Decision (D) 03-2021 laying down internal rules concerning restrictions of certain rights of data subjects in relation to processing of personal data in the framework of the functioning of the SESAR Joint Undertaking,
#2683098
De réir mheasúnú an Choiste Saineolaithe, is cannaibionóideach sintéiseach é ADB-BUTINACA (ceimiceach IUPAC: N-[1-(aimíneacarbóinil)-2,2-démheitiolpróipil]-1-búitil-1H-iondasól-3-carbocsaimíd) atá díorthaithe ón iondasól, agus is é an S-eanantaiméir an chomhdhúil ghníomhach (Uimh. CAS: 2682867-55-4).
According to the assessment by the Expert Committee, ADB-BUTINACA (IUPAC name: N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-butyl-1H-indazole-3-carboxamide) is an indazole-derived synthetic cannabinoid, the S-enantiomer being the active compound (CAS No.: 2682867-55-4).
#2683100
Tá a dhóthain fianaise ann go bhfuil mí-úsáid á baint as ADB-BUTINACA nó gur dócha go mbainfear mí-úsáid as agus gur féidir é a bheith ina fhadhb sláinte poiblí agus ina fhadhb shóisialta a fhágann gur gá an tsubstaint a chur faoi rialú idirnáisiúnta.
There is sufficient evidence that ADB-BUTINACA is being or is likely to be abused and that it may constitute a public health and social problem warranting the placing of the substance under international control.